CVS Health Corporation provides health services in the United States.
$89.35-0.49%
报价 2026-11-13
市值
$114.32B
EV
$175.78B
PE (TTM)
51.2x
预期 PE (FY2026)
10.9x
52 周区间距高点 -19.2%
$70.08$110.60
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 8.33 → 8.66（1.0x） | 10.3 |
| FY+32028-12 | 1.1x | 8.33 → 9.81（1.2x） | 9.1 |
毛利率 14% · TTM 收入 $420614M · 基数 EPS 8.33（调整后）
电话会信号
辅助标签Q3 20262026-11-04
上调指引盈利拐点
指引 上调
信心 5
分析师 3
“We now expect to deliver at least $8.65 in adjusted EPS in 2027, reflecting approximately 13% growth off an adjusted 2026 baseline.”
原文引用（2）
- 上调指引：we are raising our full-year 2026 adjusted earnings per share guidance to at least $8.20, an increase from our prior range of $7.90 to $8.10
- 盈利拐点：We are moving into the profitable territory in 2026, so I can confirm that.
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CVSCVS Health Corporation | $114.32B | -0.5% | +5.2% | 13.8% | 51.2x | 17.8x | 7.3x | |
| VRTXVertex Pharmaceuticals Incorporated | $136.56B | -0.7% | +10.6% | 86.3% | 29.0x | 23.5x | 42.6x | |
| MDTMedtronic plc | $131.58B | +1.9% | +8.0% | 62% | 24.2x | 14.8x | – | |
| BMYBristol-Myers Squibb Company PFD CONV 2 | $129.66B | +1.8% | +4.6% | 67.7% | 16.5x | 10.5x | 14.0x | |
| MCKMcKesson Corporation | $127.33B | +2.4% | +6.5% | 3.6% | 24.9x | 17.6x | 18.4x | |
| HCAHCA Healthcare, Inc. | $104.25B | -0.3% | +4.5% | 14.9% | 16.7x | 9.9x | 17.7x | |
| GSKGSK plc | $101.13B | +0.5% | – | 72.5% | 13.7x | 7.8x | – | |
| ELVElevance Health Inc. | $92.84B | -0.0% | +0.7% | 25.6% | 11.3x | 9.1x | 14.3x | |
| CICigna Corporation | $78.26B | +0.2% | +5.9% | 9.5% | 11.7x | 7.8x | 9.5x | Cheap |
| 同行中位数 | – | – | +5.9% | 43.8% | 16.6x | 10.2x | 16.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。